<DOC>
	<DOCNO>NCT00526669</DOCNO>
	<brief_summary>The study determine change expression marker involve 5-FU pathway associate response treatment combination lapatinib capecitabine independent tumor erbB2 status .</brief_summary>
	<brief_title>Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Has sign inform consent Untreated , newly diagnose , advanced metastatic unresectable gastric cancer , include gastroesophageal junction Tumor accessible patient consent endoscopic biopsy study start 7 day single agent Lapatinib Measurable disease accord RECIST criterion Male female &gt; = 18 year age Cardiac ejection fraction within institutional range normal measure echocardiogram must adequate organ function define baseline laboratory value Gastric carcinoid , sarcoma , squamous cell cancer Pregnant lactating female Intractable nausea , vomit , gastro intestinal obstruction require decompression drainage gastric tube nasogastric suction . patient require continuous enteral feed Malabsorption syndrome uncontrolled inflammatory GI disease ( Crohn 's ulcerative colitis Known history uncontrolled symptomatic angina , arrhythmia , congestive heart failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>tumor biopsy</keyword>
	<keyword>capecitabine</keyword>
	<keyword>first line</keyword>
	<keyword>Gastro Esophageal ( GE ) Junction Cancer</keyword>
	<keyword>Gastric cancer</keyword>
	<keyword>newly diagnose</keyword>
	<keyword>GE junction</keyword>
	<keyword>lapatinib</keyword>
	<keyword>metastatic unresectable</keyword>
</DOC>